Each compound carries its own trial record, and the combination case is built by reading those records together with the CagriSema precedent
Ispoglou T, White H, Preston T, McElhone S, McKenna J, Hind K
the cascade of issues attached to the drugs was similarly unknown
The clinical data gives a clear answer, and it's more nuanced than the headlines suggest
External resources Efficacy and safety of retatrutide: systematic review and meta-analysis (PMC) Triple hormone receptor agonist retatrutide for obesity: Phase 2 trial (NEJM) Tesamorelin clinical pharmacology and safety (NCBI LiverTox) Safety and metabolic effects of tesamorelin in type 2 diabetes (PMC) Tesamorelin prescribing information and side effects (Mayo Clinic) Retatrutide for metabolic dysfunction-associated steatotic liver disease (Nature Medicine) For researchers serious about optimizing their peptide protocols, SeekPeptides offers the most comprehensive resource available, with evidence-based guides, proven protocols, and a community of thousands who have navigated these exact questions